Detail page

Knowledge Web

Person

Sven Mahner (1975-)

Gynäkologe

Name	Sven Mahner
Time	1975- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Priv.-Doz. Dr. med.
Profession	Gynäkologe (characteristic profession) Arzt
Related	Universitätsklinikum Hamburg-Eppendorf
Further information	Diss. Medizinische Fakultät, Innere Medizin IV Universitätsklinik Heidelberg Univ. Hamburg, Medizinische Fak., Universitätsklinikum Hamburg-Eppendorf, Zentrum für Operative Medizin, Klinik und Poliklinik für Gynäkologie, Oberarzt und Koordinator des Gynäkologischen Krebszentrums
Source	http://www.uke.de/kliniken/frauenklinik/images_content/klinik-gynaekologie/Lebenslauf_PD_Mahner_April_2012.pdf
Record type	Person
GND-Identifier	130244775
Record ID	130244775
Involved in show all Association of four interleukin-8 polymorphisms (−251 A>T, +781 C>T, +1633 C>T, +2767 A>T) with ovarian cancer risk: focus on menopausal status and endometriosis-related subtypes Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ) Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study T-cell density at the invasive margin and immune phenotypes predict outcome in vulvar squamous cell cancer Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study Role of pelvic lymph node resection in vulvar squamous cell cancer: a subset analysis of the ago-care-1 study Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study Factors associated with the decline of psychological support in hospitalized patients with cancer TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study Klinische und histopathologische Prognosefaktoren von Borderline-Tumoren des Ovars - Analyse des UKE-Kollektivs von 1993 bis 2009 Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients Expression und Lokalisation der Multidrug-resistance-Proteine 2 und 3 im Rattendarm

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Sven Mahner (1975-)

Association of four interleukin-8 polymorphisms (−251 A>T, +781 C>T, +1633 C>T, +2767 A>T) with ovarian cancer risk: focus on menopausal status and endometriosis-related subtypes

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)

Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study

T-cell density at the invasive margin and immune phenotypes predict outcome in vulvar squamous cell cancer

Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study

Role of pelvic lymph node resection in vulvar squamous cell cancer: a subset analysis of the ago-care-1 study

Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study

Factors associated with the decline of psychological support in hospitalized patients with cancer

TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study

Klinische und histopathologische Prognosefaktoren von Borderline-Tumoren des Ovars - Analyse des UKE-Kollektivs von 1993 bis 2009

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study

Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients

Expression und Lokalisation der Multidrug-resistance-Proteine 2 und 3 im Rattendarm